Antibody acquisition after second and third SARS-CoV-2 vaccinations in Japanese kidney transplant patients: a prospective study
Background Kidney transplant patients have lower antibody acquisition after SARS-CoV-2 vaccination. The efficacy of vaccines in Japanese kidney transplant patients with specific characteristics, such as predominant living-donor, ABO-incompatible kidney transplant, and low-dose immunosuppression, req...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental nephrology 2023-06, Vol.27 (6), p.574-582 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 582 |
|---|---|
| container_issue | 6 |
| container_start_page | 574 |
| container_title | Clinical and experimental nephrology |
| container_volume | 27 |
| creator | Deguchi, Hidetaka Sakamoto, Atsuhiko Nakamura, Nobuyuki Okabe, Yasuhiro Miura, Yoshifumi Iida, Takeshi Yoshimura, Michinobu Haga, Nobuhiro Nabeshima, Shigeki Masutani, Kosuke |
| description | Background
Kidney transplant patients have lower antibody acquisition after SARS-CoV-2 vaccination. The efficacy of vaccines in Japanese kidney transplant patients with specific characteristics, such as predominant living-donor, ABO-incompatible kidney transplant, and low-dose immunosuppression, requires verification.
Methods
We conducted a prospective study to estimate anti-SARS-CoV-2 antibody levels in 105 kidney transplant patients and 57 controls. Blood samples were obtained before vaccination, 1, 3, and 6 months after second vaccination, and 1 month after third vaccination. We investigated antibody acquisition rates, antibody levels, and factors associated with antibody acquisition.
Results
One month after second vaccination, antibody acquisition was 100% in the controls but only 36.7% in the kidney transplant group (
P
|
| doi_str_mv | 10.1007/s10157-023-02334-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10010649</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2786810851</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-6bda62cc3e712b122de399a43401506f3c43966adafd7442d9555b86312dc8bd3</originalsourceid><addsrcrecordid>eNp9kctuFDEQRS0EIiHwAyyQl2wMfnW7zQaNRuGlSEgE2FrVtjtxmLE7tnukWfHreJgQwYZFyZbq1K3HReg5o68Ypep1YZR1ilAuDiEkoQ_QKZNCEaW0ftj-QnLCVMdO0JNSbiilg-70Y3Qies3kwOUp-rmKNYzJ7THY2yWUUEOKGKbqMy7epugwtKjXITt8ufpySdbpO-F4B9aGCAe64BDxJ5gh-uLxj-Ci3-OaIZZ5A7HiuVE-1vIGA55zKrO3New8LnVx-6fo0QSb4p_dvWfo27vzr-sP5OLz-4_r1QWxkvNK-tFBz60VXjE-Ms6dF1qDFLKdgPaTsFLovgcHk1NScqe7rhuHXjDu7DA6cYbeHnXnZdx6Z9tAGTZmzmELeW8SBPNvJoZrc5V2pl2a0V7qpvDyTiGn28WXarahWL9pO_q0FMPV0A-MDh1rKD-itq1bsp_u-zB6EFTmaJ1ptpnf1hnail78PeF9yR-vGiCOQGmpeOWzuUlLju1q_5P9BafrpwA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2786810851</pqid></control><display><type>article</type><title>Antibody acquisition after second and third SARS-CoV-2 vaccinations in Japanese kidney transplant patients: a prospective study</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Deguchi, Hidetaka ; Sakamoto, Atsuhiko ; Nakamura, Nobuyuki ; Okabe, Yasuhiro ; Miura, Yoshifumi ; Iida, Takeshi ; Yoshimura, Michinobu ; Haga, Nobuhiro ; Nabeshima, Shigeki ; Masutani, Kosuke</creator><creatorcontrib>Deguchi, Hidetaka ; Sakamoto, Atsuhiko ; Nakamura, Nobuyuki ; Okabe, Yasuhiro ; Miura, Yoshifumi ; Iida, Takeshi ; Yoshimura, Michinobu ; Haga, Nobuhiro ; Nabeshima, Shigeki ; Masutani, Kosuke</creatorcontrib><description>Background
Kidney transplant patients have lower antibody acquisition after SARS-CoV-2 vaccination. The efficacy of vaccines in Japanese kidney transplant patients with specific characteristics, such as predominant living-donor, ABO-incompatible kidney transplant, and low-dose immunosuppression, requires verification.
Methods
We conducted a prospective study to estimate anti-SARS-CoV-2 antibody levels in 105 kidney transplant patients and 57 controls. Blood samples were obtained before vaccination, 1, 3, and 6 months after second vaccination, and 1 month after third vaccination. We investigated antibody acquisition rates, antibody levels, and factors associated with antibody acquisition.
Results
One month after second vaccination, antibody acquisition was 100% in the controls but only 36.7% in the kidney transplant group (
P
< 0.001). Antibody levels in positive kidney transplant patients were also lower than in the controls (median, 4.9 arbitrary units vs 106.4 arbitrary units, respectively,
P
< 0.001). Years after kidney transplant (odds ratio 1.107, 95% confidence interval 1.012–1.211), ABO-incompatible kidney transplant (odds ratio 0.316, 95% confidence interval 0.101–0.991) and mycophenolate mofetil use (odds ratio 0.177, 95% confidence interval 0.054–0.570) were significant predictors for antibody acquisition after second vaccination. After third vaccination, antibody positivity in the kidney transplant group increased to 75.3%, and antibody levels in positive patients were 71.7 arbitrary units. No factors were associated with de novo antibody acquisition.
Conclusions
In Japanese kidney transplant patients, years after kidney transplant, ABO-incompatible kidney transplant and mycophenolate mofetil use were predictors for antibody acquisition after second vaccination. Third vaccination improves antibody status even in patients who were seronegative after the second vaccination.</description><identifier>ISSN: 1342-1751</identifier><identifier>EISSN: 1437-7799</identifier><identifier>DOI: 10.1007/s10157-023-02334-0</identifier><identifier>PMID: 36914824</identifier><language>eng</language><publisher>Singapore: Springer Nature Singapore</publisher><subject>Antibodies, Viral ; COVID-19 - prevention & control ; COVID-19 Vaccines - immunology ; East Asian People ; Humans ; Kidney Transplantation ; Medicine ; Medicine & Public Health ; Mycophenolic Acid - therapeutic use ; Nephrology ; Original ; Original Article ; Prospective Studies ; SARS-CoV-2 ; Transplant Recipients ; Urology ; Vaccination</subject><ispartof>Clinical and experimental nephrology, 2023-06, Vol.27 (6), p.574-582</ispartof><rights>The Author(s), under exclusive licence to The Japanese Society of Nephrology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to The Japanese Society of Nephrology.</rights><rights>The Author(s), under exclusive licence to The Japanese Society of Nephrology 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c422t-6bda62cc3e712b122de399a43401506f3c43966adafd7442d9555b86312dc8bd3</cites><orcidid>0000-0001-9190-4600</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10157-023-02334-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10157-023-02334-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,315,781,785,886,27929,27930,41493,42562,51324</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36914824$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Deguchi, Hidetaka</creatorcontrib><creatorcontrib>Sakamoto, Atsuhiko</creatorcontrib><creatorcontrib>Nakamura, Nobuyuki</creatorcontrib><creatorcontrib>Okabe, Yasuhiro</creatorcontrib><creatorcontrib>Miura, Yoshifumi</creatorcontrib><creatorcontrib>Iida, Takeshi</creatorcontrib><creatorcontrib>Yoshimura, Michinobu</creatorcontrib><creatorcontrib>Haga, Nobuhiro</creatorcontrib><creatorcontrib>Nabeshima, Shigeki</creatorcontrib><creatorcontrib>Masutani, Kosuke</creatorcontrib><title>Antibody acquisition after second and third SARS-CoV-2 vaccinations in Japanese kidney transplant patients: a prospective study</title><title>Clinical and experimental nephrology</title><addtitle>Clin Exp Nephrol</addtitle><addtitle>Clin Exp Nephrol</addtitle><description>Background
Kidney transplant patients have lower antibody acquisition after SARS-CoV-2 vaccination. The efficacy of vaccines in Japanese kidney transplant patients with specific characteristics, such as predominant living-donor, ABO-incompatible kidney transplant, and low-dose immunosuppression, requires verification.
Methods
We conducted a prospective study to estimate anti-SARS-CoV-2 antibody levels in 105 kidney transplant patients and 57 controls. Blood samples were obtained before vaccination, 1, 3, and 6 months after second vaccination, and 1 month after third vaccination. We investigated antibody acquisition rates, antibody levels, and factors associated with antibody acquisition.
Results
One month after second vaccination, antibody acquisition was 100% in the controls but only 36.7% in the kidney transplant group (
P
< 0.001). Antibody levels in positive kidney transplant patients were also lower than in the controls (median, 4.9 arbitrary units vs 106.4 arbitrary units, respectively,
P
< 0.001). Years after kidney transplant (odds ratio 1.107, 95% confidence interval 1.012–1.211), ABO-incompatible kidney transplant (odds ratio 0.316, 95% confidence interval 0.101–0.991) and mycophenolate mofetil use (odds ratio 0.177, 95% confidence interval 0.054–0.570) were significant predictors for antibody acquisition after second vaccination. After third vaccination, antibody positivity in the kidney transplant group increased to 75.3%, and antibody levels in positive patients were 71.7 arbitrary units. No factors were associated with de novo antibody acquisition.
Conclusions
In Japanese kidney transplant patients, years after kidney transplant, ABO-incompatible kidney transplant and mycophenolate mofetil use were predictors for antibody acquisition after second vaccination. Third vaccination improves antibody status even in patients who were seronegative after the second vaccination.</description><subject>Antibodies, Viral</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Vaccines - immunology</subject><subject>East Asian People</subject><subject>Humans</subject><subject>Kidney Transplantation</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mycophenolic Acid - therapeutic use</subject><subject>Nephrology</subject><subject>Original</subject><subject>Original Article</subject><subject>Prospective Studies</subject><subject>SARS-CoV-2</subject><subject>Transplant Recipients</subject><subject>Urology</subject><subject>Vaccination</subject><issn>1342-1751</issn><issn>1437-7799</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctuFDEQRS0EIiHwAyyQl2wMfnW7zQaNRuGlSEgE2FrVtjtxmLE7tnukWfHreJgQwYZFyZbq1K3HReg5o68Ypep1YZR1ilAuDiEkoQ_QKZNCEaW0ftj-QnLCVMdO0JNSbiilg-70Y3Qies3kwOUp-rmKNYzJ7THY2yWUUEOKGKbqMy7epugwtKjXITt8ufpySdbpO-F4B9aGCAe64BDxJ5gh-uLxj-Ci3-OaIZZ5A7HiuVE-1vIGA55zKrO3New8LnVx-6fo0QSb4p_dvWfo27vzr-sP5OLz-4_r1QWxkvNK-tFBz60VXjE-Ms6dF1qDFLKdgPaTsFLovgcHk1NScqe7rhuHXjDu7DA6cYbeHnXnZdx6Z9tAGTZmzmELeW8SBPNvJoZrc5V2pl2a0V7qpvDyTiGn28WXarahWL9pO_q0FMPV0A-MDh1rKD-itq1bsp_u-zB6EFTmaJ1ptpnf1hnail78PeF9yR-vGiCOQGmpeOWzuUlLju1q_5P9BafrpwA</recordid><startdate>20230601</startdate><enddate>20230601</enddate><creator>Deguchi, Hidetaka</creator><creator>Sakamoto, Atsuhiko</creator><creator>Nakamura, Nobuyuki</creator><creator>Okabe, Yasuhiro</creator><creator>Miura, Yoshifumi</creator><creator>Iida, Takeshi</creator><creator>Yoshimura, Michinobu</creator><creator>Haga, Nobuhiro</creator><creator>Nabeshima, Shigeki</creator><creator>Masutani, Kosuke</creator><general>Springer Nature Singapore</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9190-4600</orcidid></search><sort><creationdate>20230601</creationdate><title>Antibody acquisition after second and third SARS-CoV-2 vaccinations in Japanese kidney transplant patients: a prospective study</title><author>Deguchi, Hidetaka ; Sakamoto, Atsuhiko ; Nakamura, Nobuyuki ; Okabe, Yasuhiro ; Miura, Yoshifumi ; Iida, Takeshi ; Yoshimura, Michinobu ; Haga, Nobuhiro ; Nabeshima, Shigeki ; Masutani, Kosuke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-6bda62cc3e712b122de399a43401506f3c43966adafd7442d9555b86312dc8bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antibodies, Viral</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Vaccines - immunology</topic><topic>East Asian People</topic><topic>Humans</topic><topic>Kidney Transplantation</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mycophenolic Acid - therapeutic use</topic><topic>Nephrology</topic><topic>Original</topic><topic>Original Article</topic><topic>Prospective Studies</topic><topic>SARS-CoV-2</topic><topic>Transplant Recipients</topic><topic>Urology</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Deguchi, Hidetaka</creatorcontrib><creatorcontrib>Sakamoto, Atsuhiko</creatorcontrib><creatorcontrib>Nakamura, Nobuyuki</creatorcontrib><creatorcontrib>Okabe, Yasuhiro</creatorcontrib><creatorcontrib>Miura, Yoshifumi</creatorcontrib><creatorcontrib>Iida, Takeshi</creatorcontrib><creatorcontrib>Yoshimura, Michinobu</creatorcontrib><creatorcontrib>Haga, Nobuhiro</creatorcontrib><creatorcontrib>Nabeshima, Shigeki</creatorcontrib><creatorcontrib>Masutani, Kosuke</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical and experimental nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Deguchi, Hidetaka</au><au>Sakamoto, Atsuhiko</au><au>Nakamura, Nobuyuki</au><au>Okabe, Yasuhiro</au><au>Miura, Yoshifumi</au><au>Iida, Takeshi</au><au>Yoshimura, Michinobu</au><au>Haga, Nobuhiro</au><au>Nabeshima, Shigeki</au><au>Masutani, Kosuke</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibody acquisition after second and third SARS-CoV-2 vaccinations in Japanese kidney transplant patients: a prospective study</atitle><jtitle>Clinical and experimental nephrology</jtitle><stitle>Clin Exp Nephrol</stitle><addtitle>Clin Exp Nephrol</addtitle><date>2023-06-01</date><risdate>2023</risdate><volume>27</volume><issue>6</issue><spage>574</spage><epage>582</epage><pages>574-582</pages><issn>1342-1751</issn><eissn>1437-7799</eissn><abstract>Background
Kidney transplant patients have lower antibody acquisition after SARS-CoV-2 vaccination. The efficacy of vaccines in Japanese kidney transplant patients with specific characteristics, such as predominant living-donor, ABO-incompatible kidney transplant, and low-dose immunosuppression, requires verification.
Methods
We conducted a prospective study to estimate anti-SARS-CoV-2 antibody levels in 105 kidney transplant patients and 57 controls. Blood samples were obtained before vaccination, 1, 3, and 6 months after second vaccination, and 1 month after third vaccination. We investigated antibody acquisition rates, antibody levels, and factors associated with antibody acquisition.
Results
One month after second vaccination, antibody acquisition was 100% in the controls but only 36.7% in the kidney transplant group (
P
< 0.001). Antibody levels in positive kidney transplant patients were also lower than in the controls (median, 4.9 arbitrary units vs 106.4 arbitrary units, respectively,
P
< 0.001). Years after kidney transplant (odds ratio 1.107, 95% confidence interval 1.012–1.211), ABO-incompatible kidney transplant (odds ratio 0.316, 95% confidence interval 0.101–0.991) and mycophenolate mofetil use (odds ratio 0.177, 95% confidence interval 0.054–0.570) were significant predictors for antibody acquisition after second vaccination. After third vaccination, antibody positivity in the kidney transplant group increased to 75.3%, and antibody levels in positive patients were 71.7 arbitrary units. No factors were associated with de novo antibody acquisition.
Conclusions
In Japanese kidney transplant patients, years after kidney transplant, ABO-incompatible kidney transplant and mycophenolate mofetil use were predictors for antibody acquisition after second vaccination. Third vaccination improves antibody status even in patients who were seronegative after the second vaccination.</abstract><cop>Singapore</cop><pub>Springer Nature Singapore</pub><pmid>36914824</pmid><doi>10.1007/s10157-023-02334-0</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-9190-4600</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1342-1751 |
| ispartof | Clinical and experimental nephrology, 2023-06, Vol.27 (6), p.574-582 |
| issn | 1342-1751 1437-7799 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10010649 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Antibodies, Viral COVID-19 - prevention & control COVID-19 Vaccines - immunology East Asian People Humans Kidney Transplantation Medicine Medicine & Public Health Mycophenolic Acid - therapeutic use Nephrology Original Original Article Prospective Studies SARS-CoV-2 Transplant Recipients Urology Vaccination |
| title | Antibody acquisition after second and third SARS-CoV-2 vaccinations in Japanese kidney transplant patients: a prospective study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T21%3A09%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibody%20acquisition%20after%20second%20and%20third%20SARS-CoV-2%20vaccinations%20in%20Japanese%20kidney%20transplant%20patients:%20a%20prospective%20study&rft.jtitle=Clinical%20and%20experimental%20nephrology&rft.au=Deguchi,%20Hidetaka&rft.date=2023-06-01&rft.volume=27&rft.issue=6&rft.spage=574&rft.epage=582&rft.pages=574-582&rft.issn=1342-1751&rft.eissn=1437-7799&rft_id=info:doi/10.1007/s10157-023-02334-0&rft_dat=%3Cproquest_pubme%3E2786810851%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2786810851&rft_id=info:pmid/36914824&rfr_iscdi=true |